A Phase 1/2 Open-Label Clinical Trial of TC-110 T Cells in Adults With Relapsed Or Refractory Non-Hodgkin Lymphoma (NHL) Or Acute Lymphoblastic Leukemia (ALL)

The goal of this trial is to evaluate the safety of autologous genetically modified TC-110 T cells in adult patients with aggressive NHL (DLBCL, PMBCL, TFL, MCL), high-risk indolent NHL, or ALL. And to establish the recommended phase 2 dose (RP2D) for the NHL and ALL indications according to the observed adverse events, including potential dose-limiting toxicities (DLT). Subjects will be recruited for this study from the practices of Penn Medicine.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  acute lymbhoblatic leukemia,non-hodgkin lymphoma
• Age: Between 18 Years - 99 Years
• Gender: All